These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21591997)

  • 41. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.
    Gandhi V; Kantarjian H; Faderl S; Bonate P; Du M; Ayres M; Rios MB; Keating MJ; Plunkett W
    Clin Cancer Res; 2003 Dec; 9(17):6335-42. PubMed ID: 14695132
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase II study of low dose intravenous clofarabine for elderly patients with myelodysplastic syndrome who have failed 5-azacytidine.
    Lim SH; Mcmahan J; Zhang J; Zhang Y
    Leuk Lymphoma; 2010 Dec; 51(12):2258-61. PubMed ID: 21067443
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I trial of low-dose oral Clofarabine in myelodysplastic syndromes patients who have failed frontline therapy.
    Rudrapatna VK; Morley K; Boucher KM; Pierson AS; Shull CT; Kushner JP; Shami PJ
    Leuk Res; 2015 Aug; 39(8):835-9. PubMed ID: 26038120
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clofarabine: new drug. Children with acute lymphoblastic leukaemia: a last resort.
    Prescrire Int; 2007 Dec; 16(92):238-9. PubMed ID: 18092403
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clofarabine in the treatment of poor risk acute myeloid leukaemia.
    Krawczyk J; Ansar N; Swords R; Murphy T; MacDonagh B; Meenaghan T; Hayden P; Hayad A; Murray M; O'Dwyer M
    Hematol Oncol; 2010 Sep; 28(3):118-23. PubMed ID: 19768694
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
    Faderl S; Garcia-Manero G; Estrov Z; Ravandi F; Borthakur G; Cortes JE; O'Brien S; Gandhi V; Plunkett W; Byrd A; Kwari M; Kantarjian HM
    J Clin Oncol; 2010 Jun; 28(16):2755-60. PubMed ID: 20421540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clofarabine: in pediatric patients with acute lymphoblastic leukemia.
    Curran MP; Perry CM
    Paediatr Drugs; 2005; 7(4):259-64; discussion 265-6. PubMed ID: 16117562
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clofarabine: a size that fits all, may not fit all.
    Vij R
    Leuk Lymphoma; 2009 Mar; 50(3):309-10. PubMed ID: 19347718
    [No Abstract]   [Full Text] [Related]  

  • 49. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
    Kadia TM; Jabbour E; Kantarjian H
    Semin Oncol; 2011 Oct; 38(5):682-92. PubMed ID: 21943675
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
    Jeha S; Gaynon PS; Razzouk BI; Franklin J; Kadota R; Shen V; Luchtman-Jones L; Rytting M; Bomgaars LR; Rheingold S; Ritchey K; Albano E; Arceci RJ; Goldman S; Griffin T; Altman A; Gordon B; Steinherz L; Weitman S; Steinherz P
    J Clin Oncol; 2006 Apr; 24(12):1917-23. PubMed ID: 16622268
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nursing considerations for clofarabine in the treatment of acute lymphoblastic leukemia in children.
    McDonald LR; McCarthy CH
    Clin J Oncol Nurs; 2006 Dec; 10(6):809-15. PubMed ID: 17193947
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clofarabine in refractory Langerhans cell histiocytosis.
    Rodriguez-Galindo C; Jeng M; Khuu P; McCarville MB; Jeha S
    Pediatr Blood Cancer; 2008 Nov; 51(5):703-6. PubMed ID: 18623218
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
    Prebet T; Vey N
    Expert Opin Investig Drugs; 2011 Feb; 20(2):287-95. PubMed ID: 21192773
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.
    Jabbour E; Faderl S; Sasaki K; Kadia T; Daver N; Pemmaraju N; Patel K; Khoury JD; Bueso-Ramos C; Bohannan Z; Ravandi F; Borthakur G; Verstovsek S; Miller D; Maduike R; Hosing C; Kantarjian HM; Garcia-Manero G
    Cancer; 2017 Feb; 123(4):629-637. PubMed ID: 27741352
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clofarabine as a bridge to hematopoietic stem cell transplant.
    Thomas CM; Ippoliti C; Roboz GJ; Feldman E; Savva D; James S; van Besien K
    Leuk Lymphoma; 2017 Jan; 58(1):230-232. PubMed ID: 27240704
    [No Abstract]   [Full Text] [Related]  

  • 56. Induction of complete remission using single agent clofarabine in a patient with primary refractory acute myeloblaste leukemia.
    Douer D; Watkins K; Levine AM; Weiss JM; Marshall LC; Craig AR
    Leuk Lymphoma; 2003 Dec; 44(12):2135-6. PubMed ID: 14959859
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current and future management options for myelodysplastic syndromes.
    Bryan J; Jabbour E; Prescott H; Garcia-Manero G; Issa JP; Kantarjian H
    Drugs; 2010 Jul; 70(11):1381-94. PubMed ID: 20614946
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acute myeloid leukemia and ischemic heart disease successful first line treatment with clofarabine as single agent.
    Capria S; Trisolini SM; Matturro A; Santini L; Cardarelli L; Foà R; Meloni G
    Leuk Res; 2009 Dec; 33(12):e230-1. PubMed ID: 19646753
    [No Abstract]   [Full Text] [Related]  

  • 59. Fatal skin and liver toxicity in a patient treated with clofarabine.
    Johnston DL; Mandel KM
    Pediatr Blood Cancer; 2008 May; 50(5):1082. PubMed ID: 17957757
    [No Abstract]   [Full Text] [Related]  

  • 60. Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia.
    Choi J; Foss F
    Yale J Biol Med; 2006 Dec; 79(3-4):169-72. PubMed ID: 17940627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.